A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Inclusion Criteria:
Exclusion Criteria:
Scottsdale, Arizona 85251, United States
Northridge, California 91324, United States
San Jose, California 95117, United States
Thousand Oaks, California 91360, United States
Cutler Bay, Florida 33157, United States
Miami, Florida 33145, United States
New Port Richey, Florida 34653, United States
Sarasota, Florida 34239, United States
Annapolis, Maryland 21401, United States
Ann Arbor, Michigan 48109, United States
St Louis, Missouri 63141, United States
Middletown, New York 10940, United States
New York, New York 10029, United States
Charlotte, North Carolina 28273, United States
Charlotte, North Carolina 28287, United States
DuBois, Pennsylvania 15801, United States
Pittsburgh, Pennsylvania 15241, United States
Pottstown, Pennsylvania 19464, United States
Anderson, South Carolina 29621, United States
Charleston, South Carolina 29414, United States
Boerne, Texas 78006, United States
Recife, Pernambuco 50070-550, Brazil
Porto Alegre, Rio Grande do Sul 90610-000, Brazil
Rio de Janeiro, 22241-180, Brazil
Lochner ROAD, PRETORIA, South Africa